CheckMate 9DW, 2024 NCT04039607
nivolumab plus ipilimumab plus SoC (n=-9) vs. VEGF(R) inhibitor (n=-9)
randomized controlled trial
nivolumab and ipilimumab
Opdivo 1mg/kg plus Yervoy 3 mg/kg Q3W for up to four doses, followed by Opdivo monotherapy 480 mg Q4W
sorafenib or lenvatinib (investigator's choice)
mHCC - 1st line (L1)
open-label
results from press release 03/20/2024